2026 accounting cpe, 2026 accounting pharma cpe, 2026 gross to net cpe, 2026 life science accouniting cpe, 2026 life science cpe
Life Science Technical Accounting Update 2026
VIRTUAL CONFERENCE
The life science industry continues to face rapid change—new ASUs, evolving revenue models, digital transformation, and increasingly complex reporting expectations. The Life Science Technical Accounting Update 2026 is a two-day virtual 16 CPE conference designed to help finance and accounting teams stay ahead of these developments with guidance tailored specifically to biotech, pharma, and med-tech companies.
This program goes beyond the standards to focus on real-world application. Sessions will cover select ASUs, practical uses of AI and digital transformation in accounting operations, and the most challenging revenue recognition issues facing life science organizations
This program goes beyond the standards to focus on real-world application. Sessions will cover select ASUs, practical uses of AI and digital transformation in accounting operations, and the most challenging revenue recognition issues facing life science organizations
LEARNING OBJECTIVES:
- Understand the latest accounting updates and ASUs most relevant to life science companies
- Identify key timelines, implementation considerations, and factors influencing industry-specific reporting
- Gain practical insight into applying AI and digital solutions within life science accounting and finance functions
REGISTRATION INFORMATION:
Cost: $695
This event will run 8:45-4:55p (Eastern Time) each day.
Register any one of three ways:
1. Register online using a credit card and click the orange button
2. Register by phone at (610) 789-3110
3. Email your contact info to be invoiced to [email protected]
| Agenda: DAY 1 | ||
|---|---|---|
| 8:45 | 10:10 | Life Science Industry Overview Sector Landscape Miodalities and development pathway Business models and capital formation CFO, accounting and tax lens Regulatory and reinforcement Strategic trends Governance and risk |
| 10:10 | 10:30 | Break |
| 10:30 | 12:00 | Gross to Net & Inventory Accounting Gross to Net Introduction and Overview Industry View Estimation Methodology Approaching Launch Key Challenges SEC Comments Close and Financial Reporting GTN Hot Topics Discussion Inventory Accounting Refresh |
| 12:00 | 12:45 | Lunch Break |
| 1:2:45 | 2:05 | Revenue Recognition for Collaboration & License Agreements Analyze key 606 considerations Understand disclosure expectations Practical approached for estimating and constraining variable consideration Review real-world examples |
| 2:05 | 2:15 | Break |
| 2:15 | 3:30 | GenAI Automation Update What works and what doesn't in corporate accounting Understanding the AI spectrum and AI agents AI in financial reporting & demo Potential impacts to your audit |
| 3:30 | 3:40 | Break |
| 3:40 | 5:00 | Budgeting and Forecasting Best Practices Real life examples of successes and failures Forecast models Leverage different technology approaches |
| Agenda: DAY 2 | ||
|---|---|---|
| 8:45 | 9:55 | Tax Update Latest legislative developments Key Tax Proposals Possible timing and other legislative priorities |
| 9:55 | 10:10 | Break |
| 10:10 | 11:30 | Accounting for Financing Arrangements in Life Sciences |
| 11:30 | 11:45 | Break |
| 11:45 | 1:10 | Accounting for R&D and Clinical Trials R&D Funding Arrangements R&D Cost Classifications Other Intangible Assets SEC Comment Letter Trends |
| 1:10 | 2:00 | Lunch Break |
| 2:00 | 3:15 | SEC & FASB Developments Affecting Life Science Companies Disaggregation of income statement expenses Improvements to income tax disclosures SEC Comment Letter trends FASB developments US regulatory updates PCAOB standard-setting and rulemaking activity |
| 3:15 | 3:30 | Break |
| 3:30 | 4:50 | SOX & Internal Controls Update Use of Gen AI Segment Reporting Control Considerations Risk Assessment refresh Deficiencies and severity assessment |
| Conference Series Speakers Include: |
|---|
| Eugene Bessacini PwC, Deals Director |
| Adam Barrow Riveron, Senior Director |
| Nick Sanfilippo Riveron, Director, Accounting Advisory & IPO |
| Glenn Snyder Riveron, Senior Director - Interim Management |
| Zara Muradali Uncommon Collective, Founder |
| Matt Norman Deloitte, Manager |
| Russ Higgins Connor Group, Partner |
| Travis Combs Riveron, Managing Director |
| Marcus Lindner Ernst & Young, Partner |
| Margaret Smith Protiviti, Managing Director |
| Nathaniel Spedalieri Ernst & Young, Senior Manager |
| Salonee Hanspal Ernst & Young, Assurance Senior Manager |
| Gia Suber Ernst & Young, Senior - Technical Accounting Advisory Group |
| Kyle Straub PwC, Director |
| Moira Klinger PwC, Director |
| Emma Nealis PwC, Manager |
| Aleks Zabreyko Connor Group, Managing Partner |
| Jeffrey Kummer Deloitte, Director of Tax Policy |
| Joshua Areola Ernst & Young, Assurance Senior Manager |
| Tim Geringer Ernst & Young, Senior Manager |
| James Bowie Ernst & Young, Managing Director, Technical Accounting Advisory Group |
| Spencer Moses Ernst & Young, FAAS Manager |
| Tanner Schnitz Ernst & Young, Technical Accounting Manager |
| James Bowie Ernst & Young, Managing Director, Technical Accounting Advisory Group |
| Randa Ghantous Connor Group, Partner |
| Matt Lepley Connor Group, Partner |
| Christie Hutchinson Riveron, Managing Director, Technical Accounting & IPO |
| Alice Chen Ernst & Young, Senior Manager |